Skip to main content

Cytomegalovirus clinical trials at UC Davis
2 research studies open to eligible people

  • A Study of the Experimental Cytomegalovirus (CMV) Vaccine (HB-101) in Kidney Transplant Patients

    open to eligible people ages 18-99

    HB-101 is a bivalent recombinant vaccine against human CMV infection. This is a randomized, placebo-controlled, phase 2 study to assess the safety, reactogenicity, immunogenicity, and efficacy of HB-101 in CMV-Seronegative patients receiving a kidney transplant from a CMV-Seropositive living donor and CMV-Seropositive patients.Patients enrolled should have a living donor kidney transplantation ideally planned between two to four months after the first injection of study drug (HB-101 or placebo).

    Sacramento, California and other locations

  • A Study of the Safety and Efficiency of Experimental Drug Maribavir in Transplant Recipients With Cytomegalovirus (CMV) Infection

    open to eligible people ages 12 years and up

    The purpose of this study is to compare the efficacy of maribavir to investigator-assigned anti-Cytomegalovirus (CMV) therapy in CMV viremia clearance in transplant recipients who are refractory or resistant to prior anti-CMV treatment.

    Sacramento, California and other locations

Last updated: